NCT04461977 is a NA clinical trial of True acupuncture in Peripheral Neuropathy Due to Chemotherapy, sponsored by Instituto Brasileiro de Controle do Cancer.

Who is sponsoring NCT04461977?

NCT04461977 is sponsored by Instituto Brasileiro de Controle do Cancer.

What drugs are being tested in NCT04461977?

Interventions in NCT04461977: True acupuncture, Sham acupuncture.

What condition does NCT04461977 study?

NCT04461977 studies Peripheral Neuropathy Due to Chemotherapy.

Is NCT04461977 still recruiting?

NCT04461977 is currently completed. Last updated 31 May 2024.

Last reviewed 2024-05-31 · How we verify

NCT04461977

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer

Completed NA Last updated 31 May 2024

What this trial tests

NA trial testing True acupuncture in Peripheral Neuropathy Due to Chemotherapy in 60 participants. Completed in 26 March 2024.

Timeline

30 January 2020

Primary endpoint
7 November 2023

26 March 2024

Quick facts

Lead sponsor	Instituto Brasileiro de Controle do Cancer
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	60
Start date	30 January 2020
Primary completion	7 November 2023
Estimated completion	26 March 2024
Sites	1 location across Brazil

Drugs / interventions tested

True acupuncture
Sham acupuncture

Conditions studied

Peripheral Neuropathy Due to Chemotherapy — all drugs for Peripheral Neuropathy Due to Chemotherapy →

Sponsor

Instituto Brasileiro de Controle do Cancer — full company profile →

Who can join

18 and older, any sex, with Peripheral Neuropathy Due to Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aims to evaluate the effectiveness of acupuncture in the treatment of chemotherapy drug paclitaxel induced peripheral neuropathy in patients with early stage breast cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Integrated Medicine for Chemotherapy-Induced Peripheral Neuropathy.
Tsai CH, Lin YH, Li YS, Ho TL, et al · · 2021 · cited 12× · PMID 34502166 · DOI 10.3390/ijms22179257
Acupuncture for peripheral neuropathy induced by paclitaxel in early-stage breast cancer: a randomized, parallel, controlled, blinded study in a Brazilian Oncologic Center (PACLILIN Study).
Ter LI, Yamada AMTD, do Nascimento Martins Basilio A, López RVM, et al · · 2026 · PMID 41543601 · DOI 10.1007/s00520-026-10315-8

Verify or expand the search:

Other recruiting trials for Peripheral Neuropathy Due to Chemotherapy

Currently open trials in the same condition.

NCT07423390 — Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy · Phase 3 · recruiting
NCT06807294 — Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT) · NA · recruiting
NCT06744816 — Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Sin · EARLY_PHASE1 · recruiting
NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
NCT06616649 — Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study. · NA · recruiting

Other Instituto Brasileiro de Controle do Cancer trials

Trials by the same sponsor.

NCT05665920 — Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiatio · NA · recruiting
NCT04669873 — Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Can · NA · recruiting
NCT04669132 — Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic · Phase 2 · completed
NCT04834570 — Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment · unknown
NCT05050890 — Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04461977 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Brasileiro de Controle do Cancer
Last refreshed: 31 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04461977.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing